C. Light Receives FDA Clearance for Retinal Eye Movement Monitor, Retitrack

C. Light Technologies announced it has received 510(k) clearence from the FDA for the Retitrack, which is designed to provide new understanding and insight into oculomotor function via the retina, providing concrete and objective metrics to medical professionals.

The Retitrack is a monocular, tabletop eye movement monitor that is intended for recording, viewing, measuring, and analyzing temporal characteristics of fixation and saccadic responses when viewing a visual stimulus, and is intended for use by health care practitioners within the healthcare setting (e.g., physician's office, clinic, laboratory).

C. Light says the Retitrack is the first retinal eye-movement monitor cleared for use within the health care field. The device operates by recording 10-second, high-resolution retinal videos at the photoreceptor level, allowing for quantification of eye motion down to 0.1 degrees. Its accompanying software extracts and analyzes both fixation (microsaccades and drift) and saccadic eye movements in real time, and generates a comprehensive summary report for clinical interpretation.

"Fixational eye movements have previously eluded clinical quantification, posing a significant challenge to health care professionals who are aiming to improve prognostic care. With our novel technology, we've unlocked the potential of one of the smallest motor movements in the human body, offering invaluable data that will drive the future of clinical care," Christy Sheehy-Bensinger, PhD, CEO and co-founder of C. Light, said in a company news release. "We are gratified that our device is cleared for marketing and that we hit our seed funding milestone. Our device and its accompanying software will revolutionize healthcare by empowering clinicians with significant new insights into an individual's oculomotor function, as opposed to existing devices reporting on retinal structure alone."